IL272757B2 - A recombinant human acid sphingomyelinase for use for treating an abnormal bone conditions, decreasing bone marrow burden and/or improving bone mineral density - Google Patents

A recombinant human acid sphingomyelinase for use for treating an abnormal bone conditions, decreasing bone marrow burden and/or improving bone mineral density

Info

Publication number
IL272757B2
IL272757B2 IL272757A IL27275720A IL272757B2 IL 272757 B2 IL272757 B2 IL 272757B2 IL 272757 A IL272757 A IL 272757A IL 27275720 A IL27275720 A IL 27275720A IL 272757 B2 IL272757 B2 IL 272757B2
Authority
IL
Israel
Prior art keywords
patient
rhasm
bone
doses
acid sphingomyelinase
Prior art date
Application number
IL272757A
Other languages
English (en)
Hebrew (he)
Other versions
IL272757B1 (en
IL272757A (en
Original Assignee
Sanofi Sa
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Genzyme Corp filed Critical Sanofi Sa
Publication of IL272757A publication Critical patent/IL272757A/en
Publication of IL272757B1 publication Critical patent/IL272757B1/en
Publication of IL272757B2 publication Critical patent/IL272757B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
IL272757A 2017-08-24 2018-08-22 A recombinant human acid sphingomyelinase for use for treating an abnormal bone conditions, decreasing bone marrow burden and/or improving bone mineral density IL272757B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549732P 2017-08-24 2017-08-24
EP17306720 2017-12-07
PCT/IB2018/056346 WO2019038685A2 (en) 2017-08-24 2018-08-22 TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE

Publications (3)

Publication Number Publication Date
IL272757A IL272757A (en) 2020-04-30
IL272757B1 IL272757B1 (en) 2024-03-01
IL272757B2 true IL272757B2 (en) 2024-07-01

Family

ID=63556374

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272757A IL272757B2 (en) 2017-08-24 2018-08-22 A recombinant human acid sphingomyelinase for use for treating an abnormal bone conditions, decreasing bone marrow burden and/or improving bone mineral density

Country Status (17)

Country Link
US (2) US11898175B2 (cg-RX-API-DMAC7.html)
EP (1) EP3672622B1 (cg-RX-API-DMAC7.html)
JP (3) JP7216075B2 (cg-RX-API-DMAC7.html)
KR (2) KR102769578B1 (cg-RX-API-DMAC7.html)
CN (2) CN118453843A (cg-RX-API-DMAC7.html)
AU (2) AU2018319565B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003541A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073648A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020001801A2 (cg-RX-API-DMAC7.html)
ES (1) ES2970423T3 (cg-RX-API-DMAC7.html)
IL (1) IL272757B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020002106A (cg-RX-API-DMAC7.html)
NZ (1) NZ762860A (cg-RX-API-DMAC7.html)
PL (1) PL3672622T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202001544VA (cg-RX-API-DMAC7.html)
TW (1) TWI791040B (cg-RX-API-DMAC7.html)
WO (1) WO2019038685A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2470199T3 (pl) * 2009-08-28 2019-11-29 Icahn School Med Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
CN112773779B (zh) * 2021-02-04 2022-08-16 上海交通大学医学院附属新华医院 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025996A2 (en) * 2009-08-28 2011-03-03 Mount Sinai School Of Medicine Of New York University Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CN1302897A (zh) 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
EP1901770B1 (en) * 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
EP2931298A4 (en) 2012-12-12 2016-07-06 Teva Pharma FUSION OF HUMAN GROWTH HORMONES AND ALBUMIN, AND FORMULATION THEREOF AND USE THEREOF
EP3004896B1 (en) 2013-06-07 2019-09-18 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025996A2 (en) * 2009-08-28 2011-03-03 Mount Sinai School Of Medicine Of New York University Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS,, ARCHIVE HISTORY FOR NCT02004691, 3 August 2017 (2017-08-03) *
MARGARET M. MCGOVERN ET AL,, DISEASE MANIFESTATIONS AND BURDEN OF ILLNESS IN PATIENTS WITH ACID SPHINGOMYELINASE DEFICIENCY (ASMD), 23 February 2017 (2017-02-23) *
MARGARET M. MCGOVERN ET AL,, NOVEL FIRST-DOSE ADVERSE DRUG REACTIONS DURING A PHASE I TRIAL OF OLIPUDASE ALFA (RECOMBINANT HUMAN ACID SPHINGOMYELINASE) IN ADULTS WITH NIEMANN-PICK DISEASE TYPE B (ACID SPHINGOMYELINASE DEFICIENCY), 2 April 2015 (2015-04-02) *
WASSERSTEIN MELISSA P ET AL,, SUCCESSFUL WITHIN-PATIENT DOSE ESCALATION OF OLIPUDASE ALFA IN ACID SPHINGOMYELINASE DEFICIENCY, 30 May 2015 (2015-05-30) *

Also Published As

Publication number Publication date
AU2018319565B2 (en) 2025-02-20
JP2020531527A (ja) 2020-11-05
EP3672622A2 (en) 2020-07-01
JP7216075B2 (ja) 2023-01-31
ES2970423T3 (es) 2024-05-28
IL272757B1 (en) 2024-03-01
TWI791040B (zh) 2023-02-01
CN111344003A (zh) 2020-06-26
KR20250025051A (ko) 2025-02-20
SG11202001544VA (en) 2020-03-30
NZ762860A (en) 2025-09-26
WO2019038685A2 (en) 2019-02-28
WO2019038685A3 (en) 2019-05-02
MX2020002106A (es) 2020-07-14
EP3672622B1 (en) 2023-11-08
MX2023010908A (es) 2023-09-27
CN118453843A (zh) 2024-08-09
KR20200044064A (ko) 2020-04-28
AU2025203384A1 (en) 2025-05-29
US20240218338A1 (en) 2024-07-04
BR112020003541A2 (pt) 2020-09-01
JP2023052459A (ja) 2023-04-11
KR102769578B1 (ko) 2025-02-20
JP2024050732A (ja) 2024-04-10
CN111344003B (zh) 2024-05-07
US20210139868A1 (en) 2021-05-13
RU2020111649A (ru) 2021-09-24
CO2020001801A2 (es) 2020-04-01
IL272757A (en) 2020-04-30
AU2018319565A1 (en) 2020-04-09
TW201919689A (zh) 2019-06-01
CA3073648A1 (en) 2019-02-28
PL3672622T3 (pl) 2024-04-02
US11898175B2 (en) 2024-02-13
JP7431356B2 (ja) 2024-02-14

Similar Documents

Publication Publication Date Title
US20240218338A1 (en) Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
Marcucci et al. Gaucher disease and bone manifestations
Schuchman et al. Types A and B niemann-pick disease
Wang et al. Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice
Langeveld et al. Bone health in patients with inborn errors of metabolism
Campistol et al. Glutaric aciduria type I: unusual biochemical presentation
Paccou et al. Cystic fibrosis-related bone disease
Hashemieh et al. Prevalence of osteoporosis among thalassemia patients from Zafar adult thalassemia clinic, Iran
Wesolek et al. Assessment of progranulin and FAM19A5 protein blood levels in patients with metabolic syndrome
RU2795570C2 (ru) Лечение патологических состояний кости у пациентов с дефицитом кислой сфингомиелиназы
BR122025022093A2 (pt) Uso de uma esfingomielinase ácida humana recombinante (rhasm) no tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida
Levi et al. Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study
Kasapkara et al. The evaluation of skeletal manifestations in patients with Gaucher disease
EP4291224A1 (en) Alkaline phosphatase polypeptides and methods of use thereof
Lee et al. Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
Elkin Arthritis, vasculitis and bone disease
Zhu et al. Serum myostatin levels are elevated in overweight patients
Younes et al. Serum Uric Acid Level Is Positively Associated With Higher Bone Mineral Density at Multiple Skeletal Sites Among Healthy Qataris
Wang et al. A study on the nutritional status and body composition of children with Hutchinson–Gilford progeria syndrome
Manoli et al. Osteoporosis in frail patients
Laron et al. Recommended by ISPED and SIMA
MISHRA KRISHNANU DUTTA¹, TRISHNA DAS* 1, DIPANKAR SAHA¹, TAPASH CHAKRABORTY¹
Özay et al. Bone Mineral Density and Lipid Metabolism After Alendronate and Strontium Ranelate Treatment
Van Coster et al. P301 Mitochondrial abnormalities in a newborn with lactic acidosis and adrenal calcifications
Misra et al. Obesity and Metabolic Syndrome